Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.70 |
| ▸ | MGAM | O43451 | 4/20 | 0.70 |
| ▸ | GBA1 | P04062 | 4/20 | 0.70 |
| ▸ | SI | P14410 | 3/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | LCT | P09848 | 1/20 | 0.70 |
| ▸ | GBA2 | Q9HCG7 | 11/20 | 0.61 |
| ▸ | UGCG | Q16739 | 3/20 | 0.61 |
| ▸ | AGL | P35573 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270637 | 1.00 | GAA (0.70) | GAAMGAMGBA1SITDP1 | |
| SCHEMBL2274019 | 0.98 | GAA (0.68) | GAAMGAMGBA1SITDP1 | |
| SCHEMBL2124249 | 0.93 | AGL (0.69) | GAAMGAMGBA1SITDP1 | |
| SCHEMBL9485658 | 0.93 | AGL (0.69) | GAAMGAMGBA1SITDP1 | |
| SCHEMBL2124252 | 0.93 | AGL (0.69) | GAAMGAMGBA1SITDP1 | |
| Miglitol SCHEMBL23892585 | 0.83 | GAA (1.00) | GAAMGAMGBA1SITDP1 | |
| Miglitol SCHEMBL6545551 | 0.83 | GAA (1.00) | GAAMGAMGBA1SITDP1 | |
| Miglitol SCHEMBL15269512 | 0.83 | GAA (1.00) | GAAMGAMGBA1SITDP1 | |
| SCHEMBL23503288 | 0.83 | GAA (1.00) | GAAMGAMGBA1SITDP1 | |
| SCHEMBL23503369 | 0.83 | GAA (1.00) | GAAMGAMGBA1SITDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339856-A1 | NOVEL PHARMACOLOGICAL CHAPERONE COMPOUNDS OF HUMAN ACID ALPHA-GLUCOSIDASE AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339856-A1 | NOVEL PHARMACOLOGICAL CHAPERONE COMPOUNDS OF HUMAN ACID ALPHA-GLUCOSIDASE AND THE THERAPEUTIC USE THEREOF | GAA, GBA3, GANAB | GAA 1/4885MGAM 15/4885GBA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.